Introduction {#Sec1}
============

Treatment of laryngeal and hypopharyngeal cancer was frustrating due to its dysfunction and poor prognosis. Surgery is the standard treatment chemoradiotherapy alone has also shown efficacy in organ preservation trials, especially for advanced diseases \[[@CR1]\]. However, some patients who have received surgery with adjuvant chemoradiotherapy after surgery, may still have a relapse. Therefore, it is of importance to improve outcomes via seeking valuable prognostic factors and identifying patients at high risk of recurrence.

Based on the tumor-node-metastasis (TNM) staging, the American Joint Committee on Cancer (AJCC) system \[[@CR2]\] is the most commonly used staging system for laryngeal and hypopharyngeal cancers, which classified the status of lymph nodes of patients by their number, size, laterality, and extra nodal extension (ENE) \[[@CR3]\]. Nevertheless, each factor's independent impact on clinical outcome remains unclear.

Lymph node ratio (LNR) or lymph node density (LND) is calculated as the number of positive lymph nodes divided by lymph node yield (LNY) removed through neck dissection \[[@CR4]\]. Several studies showed that LNR could be employed as a supplement to the TNM staging system for better assessment of survival for esophageal \[[@CR5]\], colorectal \[[@CR6], [@CR7]\], gastric \[[@CR8]\], and breast cancers \[[@CR9]\]. In addition, two meta-analyses showed that LNR might be a significant prognostic indicator for head and neck malignancies \[[@CR10]\] and oral \[[@CR11]\] squamous cell carcinomas. Several recent studies \[[@CR12]--[@CR16]\] indicated that LNR was related to survival in patients with LHSCC, and reported on various cutoff points.

In this paper, a systematic review and meta-analysis were conducted to assess the prognostic value of LNR and explore appropriate cutoff values.

Methods {#Sec2}
=======

The study was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines \[[@CR17]\].

Search strategy {#Sec3}
---------------

We searched for the combination of free text words like "laryngeal," "larynx," "hypopharyngeal," "hypopharynx," "cancer?," "carcinoma?," "neoplasm?," "lymph nodes," "nodal," "ratio," and "density," in the PubMed, Embase (via Ovid), and Cochrane library systematically to find articles on the prognostic value of LNR in LHSCC up to October 31, 2019. Medical Subject Headings (MeSH) were adopted to in combination with the Boolean operators "AND" or "OR." The detailed retrieval strategy was shown in Tables [S1](#MOESM1){ref-type="media"}, [S2](#MOESM2){ref-type="media"} and [S3](#MOESM3){ref-type="media"}. Additionally, references cited in the articles were checked and found to be available.

Study selection {#Sec4}
---------------

We had access to all published articles which evaluated the prognostic values of LNR in LHSCC, and included articles that were published in English, studied LHSCC patients with positive lymph nodes, reported calculated LND or LNR, clarified the LNR-related outcomes, and applied multivariate regression analysis to analyze the relationship between LNR and outcomes. As previous studies showed that no significant difference was noted between LSCC and HPSCC in LNR \[[@CR18]\], we combined LSCC with LSCC for analysis.

We excluded studies whose full text were unavailable, as well as studies that were published as abstracts, reviews and case reports and not focused on the association between laryngeal or hypopharyngeal cancer and LNR. For studies that may overlap in the included population, we preferred the high-quality ones.

The literature selection was carried out by two researchers (AA and HSZ) independently, and any disagreement was resolved through negotiation or seeking the help of third party.

The outcomes were overall OS, DSS and DFS. OS was defined as the period from surgery to the last follow-up or death \[[@CR19]--[@CR22]\]. DSS was referred to the period from the initial diagnosis to LHSCC-related or treatment-related death \[[@CR16], [@CR20]--[@CR22]\]. DFS was defined as the period from the surgery to the last follow-up with no evidence of recurrence or distant metastasis \[[@CR19], [@CR21], [@CR22]\].

Data abstraction {#Sec5}
----------------

Two researchers (AA and HSZ) independently extracted the following information: author, year of publication, region, type of study, population basic characteristics, tumor basic characteristics, tumor treatment, follow-up time, and outcomes. If they did not reach a consensus over conflicting results, a third reviewer would participate making a decision.

Quality assessment of eligible studies {#Sec6}
--------------------------------------

On referring to previously published meta-analyses \[[@CR11], [@CR23]\], we made the quality assessment of eligible studies based on the Reporting Recommendations for Tumor MARKer Prognostic Studies (REMARK) guidelines \[[@CR24], [@CR25]\]. The quality assessment covered the following eight domains: inclusion and exclusion criteria clarified, study design information, information of patient characteristics, information of tumor characteristics, LND or LNR measurements clarified, study outcomes defined clearly, follow-up time, and patient's attrition clarified.

Scores for each study ranged from 0 to 8, with 8 representing the highest quality and 0 the lowest \[[@CR11], [@CR23]\].

Statistical analysis {#Sec7}
--------------------

In order to assess the relationship between LNR and LHSCC, we calculated the pooled hazard ratio (HR) with a 95% confidence interval (CI). The lowest LNR value was extracted for analysis, while the original articles presented two more categories. Based on the 95% CI not coming across the null line, HR greater than 1 indicated poor prognosis in LHSCC patients with a higher LNR value. If two more studies reported an outcome, we performed data synthesis in a random-effect model. Then, we applied the Cochran Q-static and I^2^ tests to estimate heterogeneity between studies \[[@CR26]\], and a *P*-value of Q-test less than 0.05 or an I^2^ value higher than 50% indicated large heterogeneity between studies. Subsequently, the subgroup analysis and the meta-regression analysis were conducted to explore the sources of heterogeneity. The potential publication bias of eligible studies was identified using Funnel plots, the Begg's test, and the Egger's test. We considered a *p*-value of less than 0.05 statistically significant. The trim and fill method was applied to adjust the results of pooled analysis in the case of publication bias, and all statistical tests were two-sided. Statistical software Stata Version 14.0 (StataCorp, College Station, TX, 2014) was employed in the review.

Results {#Sec8}
=======

We retrieved 445 articles following the search strategy, among which 36 articles were eligible for the full-text screening process, and 13 articles \[[@CR12]--[@CR16], [@CR18]--[@CR22], [@CR27]--[@CR29]\] were included in the meta-analysis finally. Reasons for excluding studies in the full-text screening process were listed in Table [S4](#MOESM4){ref-type="media"}. The PRISMA Flow diagram is shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1PRISMA literature screening flow diagram. Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) literature screening flow diagram

Among 13 articles contributed to 4197 patients (range, 46 to 1963; median, 105), seven studies were about HPSCC, four studies were about LSCC, and the remaining two studies were bout LHSCC. All studies were published in English between 2013 and 2019, with only one study contributed to 46 patients was designed as a prospective study, and the others as retrospective studies.

Seven \[[@CR13]--[@CR16], [@CR21], [@CR22], [@CR29]\] and six studies \[[@CR12], [@CR18]--[@CR20], [@CR27], [@CR28]\] were carried out in Eastern and Western, respectively. The mean or median follow-up time of included studies, median or mean lymph node yield, and median or mean number of positive lymph nodes range from 23 to 60 months, 20 to 60, and 1 to 4, respectively. The cutoff values of LNR calculated by different methods in eligible studies varied from 0.03 to 0.14, and the lowest significant LNR reported was 0.044. The basic features of the included studies, characteristics of patients and tumors are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Table 1Main characteristics of the eligible studiesStudyYearRegionStudy periodType of studyPopulationEndpoints with HRLNR cut-offMethod of LNR determinationFollow-up time (months)Ye \[[@CR22]\]2018China2007 to 2016retrospectiveHPSCCOS, DFS\<0.07,≥0.07ROCMedian 33.1(6.1 to 110.7)Lo \[[@CR15]\]2017Taipei, China2001 to 2007retrospectiveHPSCCOS, DFS, DSS\< 0.113, ≥0.113MeanMean 51(4 to 144)Suzuki \[[@CR21]\]2016Japan2000 to 2015prospectiveHPSCCOS, DFS\< 0.09, ≥0.09Log-rank testMean ± SD45.7 ± 40.6Joo \[[@CR14]\]2015Korea1993 to 2014retrospectiveHPSCCOS, DFS\< 0.055, ≥0.055ROCMean 37(1 to 151)Hua \[[@CR13]\]2015China2000 to 2005retrospectiveHPSCCOS\< 10, \> 10%NAMedian 48(12 to 127)Yu \[[@CR29]\]2013China1965 to 2008retrospectiveHPSCCOS, DFS, DSS≤0.14, \> 0.14LNR quartilesMean 41.8(1 to 295)Wang \[[@CR27]\]2013SEER1988 to 2008retrospectiveHPSCCOS, DFS0--0.05, 0.05--0.30, \> 0.30Log-rank testMedian 23(0 to 238)Imre \[[@CR19]\]2016Turkey2006 to 2014retrospectiveLSCCOS, DFS\< 0.09, ≥0.09Univariate Cox analysisMean 33.5(6 to 94)Ryu \[[@CR16]\]2015Korea2001 to 2010retrospectiveLSCCDFS≤0.044, \> 0.044ROCMedian 53.2(2.1 to 147.1)Wang \[[@CR28]\]2014SEER1988 to 2008retrospectiveLSCCOS, DFS0--0.09, 0.09--0.20, \> 0.20Log-rank testNAKünzel \[[@CR20]\]2015Germany1980 to 2010retrospectiveLSCCDFS\< 0.09, \> 0.09/\< 0.09, \> 0.09ROCMean 53(0.1 to 229)Choi \[[@CR12]\]2019Germany2006 to 2016retrospectiveHPSCC/LSCCOS, DFS, DSS0.03ROCMedian 60(24 to 134)Grasl \[[@CR18]\]2019Austria1994 to 2018retrospectiveHPSCC/LSCCOS, DFS, DSS≤0.07, \> 0.07ROCMean ± SD55.6 ± 59.3*HPSCC* hypopharyngeal squamous cell carcinoma, *LSCC* laryngeal squamous cell carcinoma, *OS* overall survival, *DSS* disease-specific survival, *DFS* disease-free survival, *ROC* receiver operating characteristic; NA: not availableTable 2Patient and tumor characteristics of eligible studiesAuthorSampleAgeMaleTreatmentType of Neck DissectionT stageN stageSubsiteLNYPN+Ye \[[@CR22]\]93Mean 56.9 (32 to 87)98%Surgery OR Surgery with (RT OR CRT)Radical, ElectiveT1 to T4N0, N1, N2a/b/c, N3Pyriform sinus, Posterior wall, Postcricoid region,NAMean 3 (0 to 34)Lo \[[@CR15]\]120Mean 56 (35 to 89)98%Surgery OR Surgery with (RT OR CRT)Bilateral, UnilateralT1 to T4N0, N1, N2a/b/c, N3Pyriform sinus, Posterior pharyngeal wall, PostcricoidNAMean 4Suzuki \[[@CR21]\]46Median 6694%Surgery OR Surgery with (RT OR CT OR CRT)Extended radical, Modified Radical, SelectiveT1 to T4N1, N2Priform sinus, OthersMedian 59.5 (14 to 114)Median 3 (1 to 15)Joo \[[@CR14]\]105Mean 61 (35 to 80)97%Surgery OR Surgery with (RT OR CRT)Bilateral, Modified Radical, Radical, SelectiveT1 to T4N1 to N3Pyriform sinus, Posterior pharyngeal wall, Postcricoid regionMedian 54 (15 to 176)Median 3 (1 to 31)Hua \[[@CR13]\]81Median 60 (36 to 80)98%Surgery OR Surgery with (RT OR CRT)Bilateral, UnilateralT1 to T4N1 to N3Pyriform sinus, Posterior wall, Postcricoid regionMedian 47 (3 to 95)Median 2 (0 to 17)Yu \[[@CR29]\]279Mean 57.8 (34 to 85)93%RT OR RT with (CRT OR ICT OR Surgery OR Surgery with CT)Radical, Modified Radical, SelectiveT1 to T4N0 to N3Pyriform sinus, Posterior wall, Postcricoid regionMedian 20 (2 to 76)Median 2.0 (0.5 to 22.0)Wang \[[@CR27]\]916Median 61 (35 to 93)42%Surgery OR Surgery with RTNAT1 to T4a/b, TxN1 to N3Pyriform sinus, Posterior wall, Postcricoid region, Aryepiglottic fold, Overlapping lesion, HypopharynxMedian 25 (1 to 90)Median 2 (1 to 90)Imre \[[@CR19]\]101Mean 58.5 (41 to 79)95%Surgery OR Surgery with (RT OR CRT)Radical, Modified Radical, SelectiveT1 to T4N1, N2a/b/cGlottis, Supraglottis, TransglottisMean 41.8 (18 to 88)Mean 2.9 (1 to 15)Ryu \[[@CR16]\]71Median 65 (35 to 79)93%Surgery OR Surgery with (RT OR CRT)Bilateral, Modified Radical, Radical, SelectiveT1 to T4N0 to N2Supraglottis, Glottis, TransglottisMedian 52 (11 to 153),Median 4 (1 to 21)Wang \[[@CR28]\]1963NA78%Surgery ORSurgery with RTNAT1 to T4a/b, TxN1 to N3Glottis, Supraglottis, Subglottis, Laryngeal cartilage, Overlapping lesion, LarynxMedian 28 (1 to 90)Median 2 (1 to 90)Künzel \[[@CR20]\]202Median 59 (36 to 86)93.1%Surgery OR Surgery with (RT OR CRT)Unilateral or bilateral modified radicalT1 to T4N1, N2a/b/cGlottic,Supraglottic,Unspecified site of origin within the larynxMedian 27 (10 to 88)Median 2 (1 to 19)Choi \[[@CR12]\]141Median 65 (33 to 78)93.6%Surgery OR Surgery with (RT OR CRT)Radical, SelectiveT1 to T5N1 to N3Larynx, HypopharynxMedian 60 (11 to 161)Median 1 (0 to 21)Grasl \[[@CR18]\]79Median 60 (41.6 to 83)88.6%Surgery OR Surgery with (RT OR CRT/IRT)Radical, Modified Radical, SelectiveT1 to T4N0, N1, N2a/b/c, N3a/b/cLarynx, HypopharynxMedian ± SD48.0 ± 23.8NA*NA* Not available, *RT* Radiotherapy, *CT* Chemotherapy, *CRT* Chemoradiotherapy, *IRT* Radio-immune therapy, *LNY* Lymph node yield, *PN+* Positive lymph node number

The results of the quality assessment ranged from 4 to 7 (Table [3](#Tab3){ref-type="table"}). Quality scores of 8 studies \[[@CR14], [@CR16], [@CR18]--[@CR22], [@CR27]\] were more than 5, indicating that most of the studies were moderate quality. Table 3Quality assessment of eligible studiesStudyInclusion and exclusion criteriaProspective/RetrospectivePatient characteristicsTumor characteristicsLNR measurementsEndpointFollow-up periodPatients unavailable for statistical analysisQuality scaleChoi 2019 \[[@CR12]\]111100105Ye 2018 \[[@CR22]\]111101117Lo 2017 \[[@CR15]\]111100105Suzuki 2016 \[[@CR21]\]111101106Imre 2016 \[[@CR19]\]111101106Ryu 2015 \[[@CR16]\]111111107Kunzel 2015 \[[@CR20]\]111111107Joo 2015 \[[@CR14]\]111110106Hua 2015 \[[@CR13]\]011100104Wang 2014 \[[@CR28]\]111100004Yu 2013 \[[@CR29]\]111100105Wang 2013 \[[@CR27]\]111100116Grasl 2019 \[[@CR18]\]111101106*LNR* Lymph node ratio

Meta-analysis results {#Sec9}
---------------------

Among the 13 eligible studies, 12 studies \[[@CR12]--[@CR15], [@CR18]--[@CR22], [@CR27]--[@CR29]\], 12 studies \[[@CR12], [@CR14]--[@CR16], [@CR18]--[@CR22], [@CR27]--[@CR29]\] and 4 studies \[[@CR12], [@CR15], [@CR18], [@CR29]\] explored the association between LNR and OS, DSS, DFS outcomes respectively. The pooled analysis of studies reported LNR as the categorical variable showed the higher LNR values were associated with short OS (HR 1.85, 95%CI 1.47 to 2.32, 9 studies) in the random-effect model (I^2^ = 58.4%) (Fig. [2](#Fig2){ref-type="fig"}), short DSS (HR 1.99, 95%CI 1.60 to 2.48, 11 studies) in the random-effect model(I^2^ = 49.0%) (Fig. [3](#Fig3){ref-type="fig"}) and poor DFS (HR 2.04, 95%CI 1.54 to 2.71, 3 studies) in the fixed-effect model(I^2^ = 0.0%) (Fig. [4](#Fig4){ref-type="fig"}). Fig. 2Forest plot of the meta-analysis regarding the overall survival (OS). Forest plot of the meta-analysis using the random-effect model in patients with LHSCC regarding OS. OS: Overall survival; HR: Hazard ratio; LHSCC: Laryngeal and hypopharyngeal squamous cell carcinomaFig. 3Forest plot of the meta-analysis regarding the disease-specific survival (DSS). Forest plot of the meta-analysis using the random-effect model in patients with LHSCC regarding DSS. DSS: Disease-specific survival; HR: Hazard ratio; LHSCC: Laryngeal and hypopharyngeal squamous cell carcinomaFig. 4Forest plot of the meta-analysis regarding the disease-free survival (DFS). Forest plot of the meta-analysis using the fixed-effect model in patients with LHSCC regarding DFS. DFS: Disease-free survival; HR: Hazard ratio; LHSCC: Laryngeal and hypopharyngeal squamous cell carcinoma

In addition, the meta-analysis results of studies \[[@CR13], [@CR27], [@CR28]\] reported LNR as continuous variable showed that higher LNR values indicated poor OS (HR 1.88, 95%CI 1.63 to 2.17) and poor DSS (HR 2.33, 95%CI 1.97 to 2.74) in the fixed-effect model (I^2^ = 0.0%) (Fig. [3](#Fig3){ref-type="fig"}). Besides, one of the 13 studies \[[@CR12]\] could not be quantitatively synthesized with other studies because its adjusted HR was unavailable. The univariate analysis suggested that LNR was a significant factor for OS, DSS and DFS outcomes (*P* \< 0.05), while the multivariate analysis results did not favor LNR as an independent factor for OS, DSS and DFS outcomes.

The meta-regression analysis was carried out for OS outcome, but we were not able to identify factors that might affect inter-study heterogeneity. Besides, we conducted the subgroup meta-analysis to explore the sources of heterogeneity in OS outcome, but then when the studies divided into three subgroups by regions, the inter-study heterogeneity disappeared. Similarity, the pooled results suggested that high LNR were associated with short OS in Asian (HR 2.03, 95%CI 1.58 to 2.61, I^2^ = 2.6%), European (HR 2.83, 95%CI 1.67 to 4.79, I^2^ = 0.0%) and American (HR 1.35, 95%CI 1.19 to 1.52, I^2^ = 0.0%). Furthermore, the subgroup meta-analysis results based on quality scores of included studies also showed that a high LNR suggested poor survival, and the pooled HR values of subgroups with quality scores \> 5 were 2.36 (95%CI, 1.57 to 3.54) for OS and 2.35 (95%CI, 1.70 to 3.25) for DSS. In addition, the subgroup analysis for laryngeal and hypopharyngeal cancers showed that increased LNR was associated with poor prognosis regardless of the tumor sites (Table [4](#Tab4){ref-type="table"}). Table 4Subgroup analysis by tumor sitesSitesOSDSSDFSHypopharyngeal cancerHR 1.87, 95%CI 1.37 to 2.56, 6 studiesHR 1.89, 95%CI 1.47 to 2.42, 7 studiesHR 1.99, 95%CI 1.48 to 2.68, 3 studiesLaryngeal cancerHR 1.74 95%CI (1.05 to 2.88), 2 studiesHR 2.11, 95%CI (1.34 to 3.34), 3 studiesNA*OS* overall survival, *DSS* disease-specific survival, *DFS* disease-free survival, *NA* not available

Publication bias {#Sec10}
----------------

The Funnel plots of studies that reported OS (*p* \< 0.01) and DSS (*p* \< 0.01) in the meta-analysis were asymmetric. Moreover, quantitative evaluation results achieved by the Begg's and Egger's tests indicated that the publication bias was statistically significant. Five additional studies in OS (Fig. S[1](#MOESM5){ref-type="media"}) and six in DSS (Fig. S[2](#MOESM6){ref-type="media"}) that may be missed were filled with using the trim and fill method. After adjustment, the pooled HR value was 1.49 (95%CI, 1.18 to 1.88) for OS and 1.66 (95%CI, 1.33 to 2.07) DSS, indicating that the existing publication bias did not affect the final results.

Sensitivity analysis {#Sec11}
--------------------

To ensure the robustness of the pooled adjusted HR values, we ruled out the adjusted HR value of the study of Yu et al. \[[@CR29]\], which included population having received pre-operative radiation. We achieved the similar results, that is, an increased LNR value resulted in poor OS (HR: 1.89; 95%CI, 1.45 to 2.47) and DSS (HR: 2.07; 95%CI, 1.60 to 2.68).

Discussion {#Sec12}
==========

Nearly 170,000 new cases of laryngeal cancer occur worldwide each year, and more than 90,000 people die of it \[[@CR30]\]. The incidence of hypopharyngeal cancer is about a quarter of that of laryngeal cancer.

Early studies found that the incidence of positive cervical lymph node dissection of LSCC was 32.9%, and the incidence of locally advanced tumors was 70.8% \[[@CR31]\]. Cervical metastases of HPSCC usually occur more frequently in HPSCC than in LSCC, and 80% HPSCC patients undergoing initial surgery and neck dissection suffer from cervical metastases \[[@CR14], [@CR21]\]. Local lymph node metastasis could increase tumor recurrence and mortality. Thus, a staging system is needed to stratify patients, and then possibly determine which patients are more suitable for aggressive treatment.

The current TNM staging was subdivided into refined grades, which allocated one positive lymph node ≤3 cm with ENE to the N2a category, and one positive Lymph node \> 3 cm with ENE or any two or more positive lymph nodes with ENE to the N3b category \[[@CR2]\]. However, the N staging does not involve the metastatic lymph node burden as an important prognostic factor in LHSCC \[[@CR32]\], so it may underestimate the cumulative effect of burden escalation of metastatic lymph nodes \[[@CR32]\].

Since metastatic lymph node burden is one of the most important prognostic indicators of head and neck cancers \[[@CR4], [@CR32]--[@CR34]\], and can increase the recurrence rate and mortality \[[@CR33], [@CR35]\], a variety of features of lymph nodes as prognostic indicators for head and neck cancer, were investigated thoroughly. As for LHSCC, extracapsular spread (ECS) \[[@CR35]\], number of positive lymph nodes \[[@CR12], [@CR13], [@CR32]\], and lymph node yield \[[@CR18], [@CR36], [@CR37]\] were reported. In recent years, several studies suggested that LNR or LND was an independent risk factor for patients with head and neck cancers \[[@CR4], [@CR33], [@CR37]--[@CR39]\], including LHSCC \[[@CR13]--[@CR16], [@CR18], [@CR19], [@CR21], [@CR22]\], while some other studies found no significant relationship between survival and the LNR or LND for LHSCC \[[@CR12], [@CR40]\]. As a result, there is no consensus on whether LNR as a significant prognostic factor complements the TNM staging system.

The systematic review and meta-analysis suggested that high LNR values reflected significantly short OS, DSS, and DFS in LHSCC patients undergoing surgery with or without neoadjuvant therapy. The subgroup analysis by region or tumor site also proved that a LNR value was related to poor survival. Besides, the analysis of only high-quality studies obtained similar results. Although publication bias might exist in the studies included, the results adjusted by the trim and fill method demonstrated the bias made no difference to the final results. We found similar results via the sensitivity analysis.

Some studies have found that the positive lymph nodes is also an important prognostic indicator in patients suffering from LHSCC, and more positive lymph nodes predicted an increased mortality rate \[[@CR12], [@CR32]\]. Since the number of positive lymph nodes produced is influenced by the technique of neck dissection selected, the low value may mislead practitioners into making the wrong diagnosis of the actual disease \[[@CR11]\]. Besides, some believed that positive lymph nodes might be superior to LNR as a significant predictor for head and neck cancers, such as LHSCC \[[@CR3]\]. In the multicenter study based on the SEER database, data on the type of neck dissection, the protocol of pathologic review of dissection, recurrence rate, the adjuvant chemotherapy, and ECS were unavailable. Similar limitations also existed in two studies \[[@CR27], [@CR28]\] included in this meta-analysis.

Radical, modified radical, and selective neck dissection are recommended for the removal of the tumors \[[@CR1]\]. Previous studies considered lymph nodes yield might be associated with the survival of LHSCC \[[@CR36], [@CR41]\], but the lymph node yield is greatly influenced by the type of cervical lymph node dissection, and there is no universally accepted threshold up to now. Besides, lymph node hypertrophy occurring differently among individuals makes the lymph nodes yield less reliable \[[@CR11]\]. As a result, lymph node yield may not be a good indicator of the impact of positive lymph nodes on survival.

LNR is a better prognostic measurement, for it makes a combination of information on the burden of regionally metastatic disease and type of neck dissection, so it integrates the advantages of these two parameters while bypassing their disadvantages.

In this review, the cutoff values were calculated through different methods, and the lowest significant LNR value was 0.044, which is close to the lowest value of 0.025 in oral cavity cancer reported by Huang et al \[[@CR11]\]

To the best of our knowledge, this article is the first one that conducts a meta-analysis by taking LNR as a significant prognostic indicator for LHSCC. The pooled results suggested that LNR was an independent prognosticator of survival in patients with LHSCC, and might be able to group patients into different levels through the significance of adjuvant therapy.

There are some inherent limitations to this study. Firstly, the data of most studies were collected retrospectively. Thus, some important clinical information generally had low quality, which might render the survival results limited, such as ECS, adjuvant chemotherapy protocol and patient adherence. Additionally, the acquisition of clinicopathologic information might not be acceptable. On the other hand, long-term follow-up information was available for retrospective studies. Secondly, some studies did not adjust for all the significant factors in the multivariate analysis, such as whether to receive adjuvant chemotherapy. Moreover, most eligible studies identified LNR cutoff points through the analysis of time-dependent receiver operating characteristic curves which was based on the so-called optimal cut-point and might overestimate the effect of prognosis \[[@CR42]\]. Thirdly, one study \[[@CR12]\] included in the review that found LNR was not associated with survival did not report the negative adjusted HR values, and all studies included in the quantitative synthesis yielded positive results. In order to make the results more robust and reliable, we conducted a sensitivity analysis that synthesized high-quality studies and obtained similar results. Fourthly, we grouped all LHSCC to review, which may bias the accuracy of the results. But two studies \[[@CR12], [@CR18]\] exploring the prognostic value of LNR in LHSCC demonstrated that tumor site, whether laryngeal or hypopharyngeal, had no significant on OS, DSS and DFS. Besides, we analyzed the LSCC data separately from the HPSCC, and the subgroup analysis results was similar with the overall. Finally, the sample size of eligible studies was small, resulting in publication bias because positive results from small sample size studies are more likely to be published.

Conclusion {#Sec13}
==========

This review indicates that increased high LNR values are related to poor OS, DSS, and DFS in patients with LHSCC undergoing surgery with or without neoadjuvant therapy. Nevertheless, if LNR can serve as a supplement to TNM staging and improve the accuracy of tumor staging and the cutoff values we have proposed are valid, more large samples and high-quality studies are needed to verify its reliability in the future.
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